1. Home
  2. MBCN vs DSGN Comparison

MBCN vs DSGN Comparison

Compare MBCN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middlefield Banc Corp.

MBCN

Middlefield Banc Corp.

HOLD

Current Price

$37.20

Market Cap

274.2M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.47

Market Cap

528.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBCN
DSGN
Founded
1901
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
274.2M
528.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MBCN
DSGN
Price
$37.20
$9.47
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$35.00
$13.50
AVG Volume (30 Days)
15.5K
331.1K
Earning Date
01-22-2026
11-05-2025
Dividend Yield
2.27%
N/A
EPS Growth
48.42
N/A
EPS
2.61
N/A
Revenue
$75,400,000.00
N/A
Revenue This Year
$19.98
N/A
Revenue Next Year
$7.42
N/A
P/E Ratio
$14.16
N/A
Revenue Growth
16.60
N/A
52 Week Low
$22.74
$2.60
52 Week High
$37.68
$10.31

Technical Indicators

Market Signals
Indicator
MBCN
DSGN
Relative Strength Index (RSI) 65.89 62.42
Support Level $35.33 $9.00
Resistance Level $37.68 $9.67
Average True Range (ATR) 0.80 0.67
MACD 0.18 -0.05
Stochastic Oscillator 82.00 60.84

Price Performance

Historical Comparison
MBCN
DSGN

About MBCN Middlefield Banc Corp.

Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: